Adaptimmune Therapeutics Plc ADR (ADAP)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Adrian Rawcliffe
Employees:
490
60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, UNITED KINGDOM OX14 4RX
44 1235 430000

Adaptimmune Therapeutics plc focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS)

Data derived from most recent annual or quarterly report
Market Cap 160.848 Million Shares Outstanding154.661 Million Avg 30-day Volume 783.715 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.12
Price to Revenue2.5316 Debt to Equity0.0 EBITDA-105.584 Million
Price to Book Value2.1482 Operating Margin-157.8217 Enterprise Value14.629 Million
Current Ratio3.359 EPS Growth0.333 Quick Ratio2.629
1 Yr BETA 0.9797 52-week High/Low 2.65 / 1.0 Profit Margin-160.3886
Operating Cash Flow Growth-4446.2692 Altman Z-Score-4.3128 Free Cash Flow to Firm -138.163 Million
View SEC Filings from ADAP instead.

View recent insider trading info

Adaptimmune Therapeutics Plc ADR YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ADAP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADAP

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2023-06-01 by HEGDE PRITI
  • 4: filed on 2022-07-01 by BEHBAHANI ALI
  • 4: filed on 2022-07-01 by ZAKS TAL ZVI
  • 4: filed on 2022-07-01 by ALLEVA LAWRENCE M
  • 4: filed on 2022-07-01 by FUREY JOHN
  • 4: filed on 2022-07-01 by NOBLE JAMES
  • 4: filed on 2022-07-01 by SIGAL CHARLES ELLIOTT
  • 4: filed on 2022-07-01 by DUNCAN BARBARA GAYLE
  • 4: filed on 2022-07-01 by MOTT DAVID M
  • 4: filed on 2022-01-31 by PICCINA CINTIA

    • Events (8k)

  • 8-K: filed on 2023-06-01:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-30:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-22:
    Item 8.01: Other Events
  • 8-K: filed on 2023-05-16:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-11:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-06:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-06:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ALLEN ANDREW R

    • Director
    		 0 2023-06-01 1

    MENZEL GARRY E

    • Director
    		 0 2023-06-01 2

    HEGDE PRITI

    • Director
    		 0 2023-06-01 1

    PICCINA CINTIA CHIEF COMMERCIAL OFFICER

    • Officer
    		 19,535 2023-01-31 3

    BERTRAND WILLIAM C JR CHIEF OPERATING OFFICER

    • Officer
    		 7,264 2023-01-17 4

    RAWCLIFFE ADRIAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 13,351 2023-01-17 6

    WOOD GAVIN CHIEF FINANCIAL OFFICER

    • Officer
    		 1,915,056 2023-01-17 1

    TAYTON-MARTIN HELEN KATRINA CHIEF BUSINESS & STRGY OFFICER

    • Officer
    		 1,918,392 2023-01-17 1

    LUNGER JOHN CHIEF PATIENT SUPPLY OFFICER

    • Officer
    		 7,264 2023-01-17 6

    NORRY ELLIOT CHIEF MEDICAL OFFICER

    • Officer
    		 3,491 2023-01-17 4

    BREWER JOANNA ELIZABETH CHIEF SCIENTIFIC OFFICER

    • Officer
    		 1,856,808 2023-01-17 1

    MOTT DAVID M

    • Director
    		 1,000,439 2022-07-01 1

    DUNCAN BARBARA GAYLE

    • Director
    		 500,000 2022-07-01 1

    NOBLE JAMES

    • Director
    		 710,711 2022-07-01 1

    ALLEVA LAWRENCE M

    • Director
    		 816,067 2022-07-01 1

    BEHBAHANI ALI

    • Director
    		 737,050 2022-07-01 1

    SIGAL CHARLES ELLIOTT

    • Director
    		 737,050 2022-07-01 1

    ZAKS TAL ZVI

    • Director
    		 500,000 2022-07-01 1

    FUREY JOHN

    • Director
    		 500,000 2022-07-01 1

    SANDELL SCOTT D

    • 10% Owner
    		 102,478,668 2020-01-24 0

    BASKETT FOREST

    • 10% Owner
    		 102,478,668 2020-01-24 0

    SONSINI PETER W.

    • 10% Owner
    		 102,478,668 2020-01-24 0

    FLORENCE ANTHONY A. JR.

    • 10% Owner
    		 102,478,668 2020-01-24 0

    GARONE MICHAEL INTERIM CFO

    • Officer
    		 0 2019-10-01 0

    AMADO RAFAEL PRESIDENT, R&D

    • Officer
    		 17,237 2019-08-06 0

    KERR GILES FRANCIS BERTRAM

    • Director
    		 0 2019-07-02 0

    BINDER-SCHOLL GWENDOLYN KNOWLTON CHIEF TECHNOLOGY OFFICER

    • Officer
    		 2,487 2019-01-14 0

    BARRIS PETER J

    • 10% Owner
    		 94,978,668 2018-09-07 0

    BARRETT M JAMES

    • 10% Owner
    		 82,978,668 2018-09-07 0

    KERINS PATRICK J

    • 10% Owner
    		 82,978,668 2018-09-07 0

    VISWANATHAN RAVI

    • 10% Owner
    		 94,978,668 2018-09-07 0

    NEW ENTERPRISE ASSOCIATES 14, L.P.

    NEA PARTNERS 14, L.P.

    NEA 14 GP, LTD

    • 10% Owner
    		 82,978,668 2018-09-07 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    • Director
    		 4,901,310 2018-06-04 0

    THOMPSON PETER A.

    • Director
    		 4,901,310 2018-06-04 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    ISALY SAMUEL D

    • Director
    		 6,149,377 2017-03-27 0

    LAING IAN MICHAEL

    • Director
    		 0 2016-08-11 0

    KNOWLES JONATHAN KENNETH CHARLES

    • Director
    		 0 2016-08-11 0

    KOLLURI KRISHNA KITTU

    • 10% Owner
    		 59,269,000 2016-01-01 0

    WELLER HARRY R

    • 10% Owner
    		 59,269,000 2016-01-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MENZEL GARRY E - Director see footnote

    		2023-06-01 16:59:07 -0400 2023-06-01 A 200,646 a 200,646 indirect -3.7037 0.0 1 -3.7037 2

    MENZEL GARRY E - Director see footnote

    		2023-06-01 16:59:07 -0400 2023-06-01 A 200,647 a 200,647 indirect -3.7037 0.0 1 -3.7037 2

    MENZEL GARRY E - Director

    		2023-06-01 16:59:07 -0400 2023-06-01 A 209,931 a 209,931 direct -3.7037 0.0 1 -3.7037 2

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 22:15:03 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 21:45:05 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 21:15:04 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 20:45:04 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 20:15:04 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 19:45:04 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 19:15:03 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 18:45:04 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 18:15:04 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 17:45:04 UTC -0.9658 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 17:15:04 UTC -0.9658 6.0358 8400000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 16:45:04 UTC -0.9758 6.0358 8400000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 16:15:03 UTC -0.9758 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 15:45:04 UTC -0.9758 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 15:15:04 UTC -0.9758 6.0358 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 14:45:04 UTC -1.7001 6.7601 7600000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 14:15:03 UTC -1.7001 6.7601 8400000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 13:45:03 UTC -1.7001 6.7601 8400000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 13:15:03 UTC -1.7001 6.7601 8400000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2023-06-06 12:45:05 UTC -1.7001 6.7601 8400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ADAP -9000.0 shares, $-9810.0 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments